Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Lübbert M, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP. Madan V, et al. Among authors: chendamarai e. Leukemia. 2016 Aug;30(8):1672-81. doi: 10.1038/leu.2016.69. Epub 2016 Apr 11. Leukemia. 2016. PMID: 27063598 Free PMC article.
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Lübbert M, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HP. Madan V, et al. Among authors: chendamarai e. Leukemia. 2016 Dec;30(12):2430. doi: 10.1038/leu.2016.237. Epub 2016 Oct 7. Leukemia. 2016. PMID: 27713533 Free PMC article. No abstract available.
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
Ganesan S, Alex AA, Chendamarai E, Balasundaram N, Palani HK, David S, Kulkarni U, Aiyaz M, Mugasimangalam R, Korula A, Abraham A, Srivastava A, Padua RA, Chomienne C, George B, Balasubramanian P, Mathews V. Ganesan S, et al. Among authors: chendamarai e. Leukemia. 2016 Nov;30(11):2169-2178. doi: 10.1038/leu.2016.227. Epub 2016 Aug 18. Leukemia. 2016. PMID: 27560113 Free PMC article.
Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide.
Mathews V, Chendamarai E, George B, Viswabandya A, Srivastava A. Mathews V, et al. Among authors: chendamarai e. Mediterr J Hematol Infect Dis. 2011;3(1):e2011056. doi: 10.4084/MJHID.2011.056. Epub 2011 Nov 28. Mediterr J Hematol Infect Dis. 2011. PMID: 22220253 Free PMC article.
Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.
Chendamarai E, Balasubramanian P, George B, Viswabandya A, Abraham A, Ahmed R, Alex AA, Ganesan S, Lakshmi KM, Sitaram U, Nair SC, Chandy M, Janet NB, Srivastava VM, Srivastava A, Mathews V. Chendamarai E, et al. Blood. 2012 Apr 12;119(15):3413-9. doi: 10.1182/blood-2011-11-393264. Epub 2012 Feb 28. Blood. 2012. PMID: 22374701 Free article.
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N, Ganesan S, Chendamarai E, Palani HK, Venkatraman A, Alex AA, David S, Kumar SP, Radhakrishnan NR, Yasar M, Krishna S, Korula A, Kulkarni U, Janet NB, Balasubramanian P, Mathews V. Balasundaram N, et al. Among authors: chendamarai e. Blood Adv. 2022 Jan 25;6(2):652-663. doi: 10.1182/bloodadvances.2021005300. Blood Adv. 2022. PMID: 34625794 Free PMC article.
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
Chendamarai E, Ganesan S, Alex AA, Kamath V, Nair SC, Nellickal AJ, Janet NB, Srivastava V, Lakshmi KM, Viswabandya A, Abraham A, Aiyaz M, Mullapudi N, Mugasimangalam R, Padua RA, Chomienne C, Chandy M, Srivastava A, George B, Balasubramanian P, Mathews V. Chendamarai E, et al. PLoS One. 2015 Mar 30;10(3):e0121912. doi: 10.1371/journal.pone.0121912. eCollection 2015. PLoS One. 2015. PMID: 25822503 Free PMC article.
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M. Mathews V, et al. Among authors: chendamarai e. J Clin Oncol. 2010 Aug 20;28(24):3866-71. doi: 10.1200/JCO.2010.28.5031. Epub 2010 Jul 19. J Clin Oncol. 2010. PMID: 20644086 Clinical Trial.
Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P, Chendamarai E, Balasubramanian P, Velayudhan SR, Srivastava VM, Mathews V, George B, Viswabandya A, Srivastava A, Chandy M. Markose P, et al. Among authors: chendamarai e. Leuk Lymphoma. 2009 Dec;50(12):2092-5. doi: 10.3109/10428190903332486. Leuk Lymphoma. 2009. PMID: 19925053 No abstract available.
21 results